News - Orencia


Current filters:


Popular Filters

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results


Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study


US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

NICE green light for earlier use of Bristol-Myers' Orencia


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

UK's NICE draft guidance recommends Bristol-Myers Orencia for RA


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (December…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalPricingRegulation

More news at EULAR from Novartis, J&S and B-MS


Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

US FDA backs SC form of B-MS Orencia; extends review of Pfizer’s Prevnar 13


The US Food and Drug Administration has approved a subcutaneous (SC) formulation of drug major Bristol-Myers…

Anti-Arthritics/RheumaticsBristol-Myers SquibbNorth AmericaOrenciaPfizerPharmaceuticalPrevnarRegulationVaccines

Back to top